{"id":5391,"date":"2019-07-02T12:09:53","date_gmt":"2019-07-02T06:39:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5391"},"modified":"2021-07-24T12:57:26","modified_gmt":"2021-07-24T07:27:26","slug":"pharma-happenings-for-pfizer-century-therapeutics-janssen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen","title":{"rendered":"FDA&#8217;s approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics; Imbruvica&#8217;s recommendation from CHMP"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>Pfizer\u2019s Zirabev gets\nFDA nod for the treatment of five types of cancer <\/strong><\/h4>\n\n\n\n<p>The US FDA has approved <strong>Zirabev <\/strong>(bevacizumab-bvzr), a drug developed by <strong>Pfizer<\/strong>, for the treatment of five different types of cancer namely metastatic <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\">colorectal cancer<\/a>; unresectable, locally advanced, recurrent or metastatic non-squamous <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">non-small cell lung cancer<\/a> (NSCLC); recurrent <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market\">glioblastoma<\/a>; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer. Zirabev, which is a biosimilar to <strong>Roche\u2019s Avastin<\/strong> (bevacizumab), secured regulatory approval in Europe for the same in earlier this month. The drug works by inhibiting the formation of new blood cells by targeting and thereafter binding to vascular endothelial growth factor (VEGF) protein. Zirabev, after Trazimera, is the second drug by Pfizer which got FDA-approved.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong> Century Therapeutics launches with USD 250 M for iPSC Allogenic cell therapy <\/strong><\/h4>\n\n\n\n<p>A new startup <strong>Century Therapeutics<\/strong> came to life with an investment of  USD 250 Million financed jointly by Bayer, Versant and Fujifilm Cellular Dynamics Inc. Founded by <strong>Versant Venture<\/strong>, Century Therapeutics is focusing on developing induced pluripotent stem cell- (<strong>iPSC<\/strong>) based therapies for the treatment of hematologic and solid malignancies.  <br>iPSC have an unlimited self-renewing capacity, enabling multiple rounds of cellular engineering. This will help produce a master cell bank of modified cells, in the end supplying vast amounts of allogeneic and homogeneous therapeutic products. The consortium will help Philadelphia-based  Century Therapeutics to realize its potential as iPSC cell therapy platform and addressing high unmet needs in cancer treatment market. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>A positive opinion for Janssen\u2019s IMBRUVICA from CHMP <\/strong><\/h4>\n\n\n\n<p>The European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the expanding of existing market authorization (MA) for <strong>Janssen\u2019s Imbruvica<\/strong> (ibrutinib). The drug, Imbruvica, at present, is administered to adult patients suffering from, once treated, relapsed or refractory mantle cell lymphoma (MCL), or <strong>chronic lymphocytic leukaemia<\/strong> (CLL). After the CHMP recommendation, it will be used for treating <strong>chronic lymphocytic leukaemia<\/strong> (CLL) and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/waldenstrom-macroglobulinemia-market\">Waldenstr\u00f6m\u2019s macroglobulinemia<\/a><\/strong> (WM) in combination with obinutuzumab and andrituximab respectively.  <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer\u2019s Zirabev gets FDA nod for the treatment of five types of cancer The US FDA has approved Zirabev (bevacizumab-bvzr), a drug developed by Pfizer, for the treatment of five different types of cancer namely metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17736,4865,704,17737,1657,349,460,639,1196,4864,17735],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-century-therapeutics","tag-chronic-lymphocytic-leukaemia","tag-fda","tag-imbruvica","tag-janssen","tag-latest-pharma-news","tag-pfizer","tag-pharma-news","tag-pharma-research","tag-waldenstroms-macroglobulinemia","tag-zirabev","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FDA&#039;s approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics<\/title>\n<meta name=\"description\" content=\"A new startup Century Therapeutics launched with an investment of USD 250 Million...Imbruvica to be used for treating chronic lymphocytic leukaemia (CLL)...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA&#039;s approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics\" \/>\n<meta property=\"og:description\" content=\"A new startup Century Therapeutics launched with an investment of USD 250 Million...Imbruvica to be used for treating chronic lymphocytic leukaemia (CLL)...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-02T06:39:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA's approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics","description":"A new startup Century Therapeutics launched with an investment of USD 250 Million...Imbruvica to be used for treating chronic lymphocytic leukaemia (CLL)...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen","og_locale":"en_US","og_type":"article","og_title":"FDA's approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics","og_description":"A new startup Century Therapeutics launched with an investment of USD 250 Million...Imbruvica to be used for treating chronic lymphocytic leukaemia (CLL)...","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-02T06:39:53+00:00","article_modified_time":"2021-07-24T07:27:26+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen","name":"FDA's approval to Pfizer\u2019s Zirabev; Launch of Century Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","datePublished":"2019-07-02T06:39:53+00:00","dateModified":"2021-07-24T07:27:26+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A new startup Century Therapeutics launched with an investment of USD 250 Million...Imbruvica to be used for treating chronic lymphocytic leukaemia (CLL)...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-pfizer-century-therapeutics-janssen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new.png","width":647,"height":345,"caption":"Recent Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09022909\/Notizia-new-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Century Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">chronic lymphocytic leukaemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Imbruvica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Janssen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Waldenstr\u00f6m\u2019s macroglobulinemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zirabev<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Century Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">chronic lymphocytic leukaemia<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Imbruvica<\/span>","<span class=\"advgb-post-tax-term\">Janssen<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma research<\/span>","<span class=\"advgb-post-tax-term\">Waldenstr\u00f6m\u2019s macroglobulinemia<\/span>","<span class=\"advgb-post-tax-term\">Zirabev<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 2, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 2, 2019 12:09 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Recent Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5391"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5080"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5391"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5391"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}